Cardiol sets 2026 AGM and record date

Q: Which class of securities may vote at Cardiol Therapeutics’ June 24, 2026 AGM?

Holders of Class A Common shares of Cardiol Therapeutics are entitled to vote at the June 24, 2026 annual general meeting. This class is identified in the notice, which also provides the ISIN CA14161Y2006 for the voting securities.

Q: Does Cardiol Therapeutics use notice and access for AGM proxy materials?

Yes, Cardiol Therapeutics will use Notice and Access for both beneficial and registered holders for the 2026 annual general meeting. The issuer will also pay for delivery of materials to objecting beneficial owners, as outlined in the meeting notice filed via SEDAR+.

Q: Will Cardiol Therapeutics send proxy materials directly to NOBOs for the 2026 AGM?

No, the issuer will not send proxy materials directly to non-objecting beneficial owners (NOBOs). However, Cardiol Therapeutics will pay for delivery of such materials to objecting beneficial owners (OBOs) and is using notice-and-access procedures for this meeting.

Cardiol Therapeutics Inc. has scheduled its next annual general meeting of securityholders.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

Cardiol Therapeutics Inc. has scheduled its next annual general meeting of securityholders. The meeting will be held on June 24, 2026, with a record date of May 7, 2026 for both notice of meeting and voting rights, and for determining beneficial ownership.

The meeting will involve holders of Class A Common shares. The company will use notice-and-access procedures for both registered and beneficial holders and will pay for delivery of proxy materials to objecting beneficial owners. Odyssey Trust Company is acting as agent for Cardiol in this process.

Key Figures

Meeting Type: Annual General Meeting Meeting Date: June 24, 2026 Record Date: May 7, 2026 +3 more

6 metrics

Meeting Type Annual General Meeting Upcoming securityholder meeting

Meeting Date June 24, 2026 Annual general meeting of securityholders

Record Date May 7, 2026 Record date for notice and voting

Beneficial Ownership Date May 7, 2026 Beneficial ownership determination date

Voting Securities Class Class A Common Class entitled to vote at AGM

ISIN CA14161Y2006 Identifier for Class A Common voting securities

Key Terms

Record Date for Notice of Meeting, Beneficial Ownership Determination Date, Notice and Access, NOBOs, +2 more

6 terms

Record Date for Notice of Meeting financial

"Record Date for Notice of Meeting: | May 7, 2026"

Beneficial Ownership Determination Date financial

"Beneficial Ownership Determination Date: | May 7, 2026"

Notice and Access regulatory

"Notice and Access for Beneficial Holders: | Yes"

Notice and access is a delivery method regulators allow for sending shareholders a brief paper notice that tells them where to find full meeting materials and voting forms online instead of mailing long paper packets. Investors can read documents, cast votes, or request a paper copy; it speeds delivery and cuts costs like receiving a postcard with a website link instead of a thick booklet. It matters because it affects how quickly and easily investors get information and vote, and may influence participation and record-keeping.

NOBOs regulatory

"Issuer sending proxy materials directly to NOBOs: | No"

OBOs regulatory

"Issuer paying for delivery to OBOs: | Yes"

Annual General Meeting financial

"Meeting Type: | Annual General Meeting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Cardiol Therapeutics (CRDL) holding its next annual general meeting?

Cardiol Therapeutics will hold its annual general meeting of securityholders on June 24, 2026. This date is confirmed in the meeting notice filed by Odyssey Trust Company as agent for the issuer, covering holders of Class A Common shares entitled to vote.

What is the record date for Cardiol Therapeutics (CRDL) shareholders to vote at the 2026 AGM?

The record date for notice of meeting and voting at Cardiol Therapeutics’ 2026 annual general meeting is May 7, 2026. Securityholders of Class A Common recorded on this date will be entitled to receive meeting materials and exercise their voting rights.

Which class of securities may vote at Cardiol Therapeutics’ June 24, 2026 AGM?

Holders of Class A Common shares of Cardiol Therapeutics are entitled to vote at the June 24, 2026 annual general meeting. This class is identified in the notice, which also provides the ISIN CA14161Y2006 for the voting securities.

What is the beneficial ownership determination date for Cardiol Therapeutics (CRDL) 2026 AGM?

The beneficial ownership determination date for Cardiol Therapeutics’ 2026 annual general meeting is May 7, 2026. This date aligns with the record date for notice and voting, helping define which beneficial holders are recognized for meeting-related entitlements.

Does Cardiol Therapeutics use notice and access for AGM proxy materials?

Yes, Cardiol Therapeutics will use Notice and Access for both beneficial and registered holders for the 2026 annual general meeting. The issuer will also pay for delivery of materials to objecting beneficial owners, as outlined in the meeting notice filed via SEDAR+.

Will Cardiol Therapeutics send proxy materials directly to NOBOs for the 2026 AGM?

No, the issuer will not send proxy materials directly to non-objecting beneficial owners (NOBOs). However, Cardiol Therapeutics will pay for delivery of such materials to objecting beneficial owners (OBOs) and is using notice-and-access procedures for this meeting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/10/2026 - 01:13 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number: 001-40712

Cardiol Therapeutics Inc.

(Name of registrant)

602-2265 Upper Middle Road East

Oakville, Ontario L6H 0G5

Canada

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

¨   Form 20-F

x   Form 40-F

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CARDIOL THERAPEUTICS INC.
	(Registrant)

Date: April 10, 2026	By:	/s/ Christopher Waddick
		Name:	Christopher Waddick
		Title:	Chief Financial Officer

Form 6-K Exhibit Index

Exhibit Number		Document Description
99.1		Notice of Meeting and Record Date, dated April 10, 2026

Exhibit 99.1

April 10, 2026

Filed via SEDAR+

To All Applicable Exchanges and Securities Administrators

Subject:	Cardiol Therapeutics Inc. (the "Issuer")
	Notice of Meeting and Record Date

Dear Sir/Madam:

We are pleased to confirm the following information with respect to the Issuer's upcoming meeting of securityholders:

Meeting Type:	Annual General Meeting
Meeting Date:	June 24, 2026
Record Date for Notice of Meeting:	May 7, 2026
Record Date for Voting (if applicable):	May 7, 2026
Beneficial Ownership Determination Date:	May 7, 2026
Class of Securities Entitled to Vote:	Class A Common
ISIN:	CA14161Y2006
Issuer sending proxy materials directly to NOBOs:	No
Issuer paying for delivery to OBOs:	Yes
Notice and Access for Beneficial Holders:	Yes
Beneficial Holders Stratification Criteria:	Not Applicable
Notice and Access for Registered Holders:	Yes
Registered Holders Stratification Criteria:	Not Applicable

In accordance with applicable securities regulations we are filing this information with you in our capacity as agent of the Issuer.

Yours truly,

Odyssey Trust Company

as agent for Cardiol Therapeutics Inc.

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases

EX-99.1 EXHIBIT 99.1 9.8 KB